SCHEMBL1648353

SCHEMBL1648353

CCOC(=O)c1cc(-c2ccoc2)ccc1CS(=O)(=O)c1cccc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CHRNA7 P36544 3/20 0.40
HIF1A Q16665 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
HCRTR2 O43614 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.37
PPARG P37231 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SERPINE1 P05121 2/20 0.36
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648916 0.81 PPARG (0.42) KMT2AMEN1CHRNA7HIF1AHCRTR2
Chlorobenzene SCHEMBL28797250 0.80 HSD17B10 (0.35) KMT2AMEN1CHRNA7ALDH1A1PPARG
SCHEMBL1647768 0.79 NR4A2 (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL1649230 0.74 HDAC2 (0.39) SMN1; SMN2SERPINE1HSD17B10
SCHEMBL28104286 0.74 KMT2A (0.43) KMT2AMEN1CHRNA7HIF1APDE3B
SCHEMBL1648321 0.74 CYP1A2 (0.36) KMT2AMEN1ALDH1A1PPARGSERPINE1
SCHEMBL1648305 0.73 TSHR (0.40) KMT2AALDH1A1PPARG
SCHEMBL1648187 0.72 METAP2 (0.48) SERPINE1
SCHEMBL1648304 0.69 PPARG (0.40) KMT2AMEN1ALDH1A1PPARGSMN1; SMN2
SCHEMBL1648175 0.69 MEN1 (0.42) KMT2AMEN1CHRNA7HIF1AHCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS KMT2A 666/4885MEN1 1603/4885CHRNA7 4646/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS KMT2A 666/4885MEN1 1603/4885CHRNA7 4646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.